



## Edgar Filing: ELAN CORP PLC - Form 6-K

report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes / /

No /X/

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

This Report of Foreign Issuer on Form 6-K is incorporated by reference into the Post-Effective Amendments on Forms F-3 and S-8 to Form F-4 Registration Statement of Elan Corporation, plc (Registration No. 333-12756), the Registration Statement on Form F-3 of Elan Corporation, plc and Athena Neuroscience Finance, LLC (Registration No. 333-13130), and the Registration Statements on Form S-8 of Elan Corporation, plc (Registration Nos. 333-13996, 333-12344, 333-11940, 333-09644, 333-09284, 333-09048, 333-08384, 333-07361, 333-07136, 333-14240, 33-27506 and 333-100252).

### EXHIBIT LIST

Exhibit	Description
99.1	Press release dated April 13, 2005 titled: Positive one-year data from SENTINEL trial evaluating addition of TYSABRI(R) to AVONEX(R) presented at American Academy of Neurology meeting. Data from GLANCE safety study also presented.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Edgar Filing: ELAN CORP PLC - Form 6-K

ELAN CORPORATION, plc

By: /s/ William F. Daniel

-----  
William F. Daniel  
Company Secretary

Date: April 13, 2005

Exhibit 99.1

For More Information Contact:

MEDIA CONTACTS:

Biogen Idec  
Amy Brockelman  
Ph: 617 914 6524

Elan  
Anita Kawatra or  
Brian McGlynn  
Ph: 212 407 5740  
800 252 3526

INVESTOR CONTACTS:

Biogen Idec  
Elizabeth Woo  
Ph: 617 679 2812

Elan  
Emer Reynolds  
Ph: 353 1 709 4000  
800 252 3526

POSITIVE ONE-YEAR DATA FROM SENTINEL TRIAL EVALUATING ADDITION OF  
TYSABRI (R) TO AVONEX (R) PRESENTED AT  
AMERICAN ACADEMY OF NEUROLOGY MEETING

Data from GLANCE Safety Study Also Presented

Cambridge, MA and Dublin, Ireland - April 13, 2005 - One-year data from the Phase III SENTINEL trial, presented at the 57th annual American Academy of Neurology (AAN) meeting in Miami Beach, FL, demonstrated that when TYSABRI (R) (natalizumab) was added to AVONEX (R) (Interferon beta-1a) in patients with relapsing forms of multiple sclerosis (MS), the annualized clinical relapse rate was reduced by 54 percent over the effect of AVONEX alone (p